Hyperuricemia and long-term mortality in patients with acute myocardial infarction undergoing percutaneous coronary
Wei Guo1,2, Dahao Yang3, Dengxuan Wu4
1Guangdong Provincial Geriatrics Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
Insights
High serum uric acid (hyperuricemia) before percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) is linked to increased long-term mortality. This finding is independent of chronic kidney disease (CKD).
Area of Science:
- Cardiology
- Nephrology
- Biomarkers
Background:
- Serum uric acid (UA) involvement in cardiovascular disease is recognized, but its specific role as a risk factor in acute myocardial infarction (AMI) remains debated.
- The association between hyperuricemia and long-term outcomes in patients with AMI undergoing percutaneous coronary intervention (PCI) requires further investigation.
Purpose of the Study:
- To investigate the association between preprocedural hyperuricemia and long-term all-cause mortality in patients with AMI who underwent PCI.
- To determine if hyperuricemia is an independent predictor of mortality in this patient population.
Main Methods:
- A single-center study consecutively enrolled 1005 patients with AMI who received PCI.
- Preprocedural hyperuricemia was defined as serum UA levels >7 mg/dL in males and >6 mg/dL in females.
- All-cause mortality was assessed over a median follow-up period of 2.3 years.
Main Results:
- 30.5% of patients (307 out of 1005) presented with hyperuricemia.
- Multivariable analysis, after adjusting for confounding factors, revealed that preprocedural hyperuricemia was associated with an increased risk of all-cause mortality (Hazard Ratio: 1.97; 95% Confidence Interval: 1.11-3.49; P=0.019).
- The association remained significant during the 2.3-year follow-up period.
Conclusions:
- Preprocedural hyperuricemia is a significant and independent predictor of long-term mortality in patients with AMI undergoing PCI.
- This predictive value is independent of the presence of chronic kidney disease (CKD).
- Hyperuricemia should be considered a risk factor for adverse outcomes in AMI patients treated with PCI.
Background:
Although serum uric acid (UA) was regarded to be involved in cardiovascular disease, the role of serum UA (SUA) as a risk factor in acute myocardial infarction (AMI) is controversial. We investigated whether hyperuricemia was linked with long-term mortality in patients with AMI who underwent percutaneous coronary intervention (PCI).
Methods:
Patients with AMI who received PCI were consecutively included. The definition of preprocedural hyperuricemia was a SUA level >7 mg/dL (417 mmol/L) in males and >6 mg/dL (357 mmol/L) in females. All-cause mortality was assessed during 2.3-year median follow up period.
Results:
One thousand and five patients with AMI undergoing PCI were enrolled in a single center study, 307 (30.5%) patients had hyperuricemia. After adjusting for potential confounding factors, the multivariable analysis indicated that preprocedural hyperuricemia was related to an increased risk of all-cause mortality during the 2.3-year follow-up (HR: 1.97; 95% CI: 1.11-3.49; P=0.019).
Conclusions:
Preprocedural hyperuricemia, independently from chronic kidney disease (CKD), is a significant and independent predictor of long-term mortality for patients with AMI who underwent PCI.
More Related Videos
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome I: Introduction
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:14Myocarditis III: Medical Management
01:30Coronary Artery Disease I: Introduction
01:28Cardiac Catheterization I: Pre-Procedure Overview